DK1401492T3 - LTB4 som vaccineadjuvans - Google Patents

LTB4 som vaccineadjuvans

Info

Publication number: DK1401492T3
Authority: DK; Denmark
Prior art keywords: ltb4; vaccine adjuvant; vaccine; enhancing; adjuvant
Prior art date: 2001-07-05

Application number

DK02737698T

Other languages

English (en)

Inventor

Pierre Borgeat

Louis Flamand

Jean Gosselin

Original Assignee

Ltb4 Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-05

Filing date

2002-06-26

Publication date

2009-09-14

2002-06-26 Application filed by Ltb4 Sweden Ab filed Critical Ltb4 Sweden Ab

2009-09-14 Application granted granted Critical

2009-09-14 Publication of DK1401492T3 publication Critical patent/DK1401492T3/da

Links

VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 title abstract 2
239000012646 vaccine adjuvant Substances 0.000 title abstract 2
229940124931 vaccine adjuvant Drugs 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
Vending Machines For Individual Products (AREA)
Amplifiers (AREA)

DK02737698T 2001-07-05 2002-06-26 LTB4 som vaccineadjuvans DK1401492T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30270501P	2001-07-05	2001-07-05
PCT/CA2002/000955 WO2003004054A1 (en)	2001-07-05	2002-06-26	Ltb4 as vaccine aduvant

Publications (1)

Publication Number	Publication Date
DK1401492T3 true DK1401492T3 (da)	2009-09-14

Family

ID=23168877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02737698T DK1401492T3 (da)	2001-07-05	2002-06-26	LTB4 som vaccineadjuvans

Country Status (8)

Country	Link
US (1)	US7914800B2 (da)
EP (1)	EP1401492B1 (da)
AT (1)	ATE431745T1 (da)
CA (1)	CA2452008C (da)
DE (1)	DE60232413D1 (da)
DK (1)	DK1401492T3 (da)
ES (1)	ES2329118T3 (da)
WO (1)	WO2003004054A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7473708B2 (en)	1996-02-15	2009-01-06	Jean Gosselin	Agents with leukotriene B4-like antiviral (enveloped RNA) activities
WO2005102309A2 (en) *	2004-04-26	2005-11-03	Ltb4 Sweden Ab	In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
ATE474603T1 (de) *	2004-09-20	2010-08-15	Ltb4 Sweden Ab	Stabilisiertes leukotrien b4 (ltb4) pharmazeutikum
CA2803444A1 (en) *	2010-06-29	2012-01-05	Universite Laval	Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789441A (en) *	1996-02-15	1998-08-04	Virocell Inc.	Leukotriene B4 as an antiviral and anti-neoplastic agent
US5919480A (en) *	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method

2002
- 2002-06-26 WO PCT/CA2002/000955 patent/WO2003004054A1/en not_active Ceased
- 2002-06-26 DK DK02737698T patent/DK1401492T3/da active
- 2002-06-26 ES ES02737698T patent/ES2329118T3/es not_active Expired - Lifetime
- 2002-06-26 US US10/482,393 patent/US7914800B2/en not_active Expired - Fee Related
- 2002-06-26 CA CA2452008A patent/CA2452008C/en not_active Expired - Fee Related
- 2002-06-26 DE DE60232413T patent/DE60232413D1/de not_active Expired - Lifetime
- 2002-06-26 AT AT02737698T patent/ATE431745T1/de not_active IP Right Cessation
- 2002-06-26 EP EP02737698A patent/EP1401492B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2452008C (en)	2012-03-06
EP1401492A1 (en)	2004-03-31
US20040208882A1 (en)	2004-10-21
WO2003004054A1 (en)	2003-01-16
US7914800B2 (en)	2011-03-29
EP1401492B1 (en)	2009-05-20
ATE431745T1 (de)	2009-06-15
ES2329118T3 (es)	2009-11-23
CA2452008A1 (en)	2003-01-16
DE60232413D1 (en)	2009-07-02

Publication	Publication Date	Title
WO2006068663A3 (en)	2006-11-16	Vaccine compositions for treating coronavirus infection
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
DK1113816T3 (da)	2006-04-03	Influenzavirus-vaccinesammensætning
DE60210456D1 (de)	2006-05-18	Solubisierung von kapseln polysacchariden
CY2013036I2 (el)	2015-12-09	Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
PT1187629E (pt)	2005-02-28	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MA29406B1 (fr)	2008-04-01	Vaccin toxoide alpha de c. perfringens
GB2386072A (en)	2003-09-10	Novel vaccine
WO2006126981A3 (en)	2009-04-09	Compositions and methods for mucosal vaccination
DE60015084D1 (de)	2004-11-25	Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
NO20023935L (no)	2002-10-15	Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
DK1265633T3 (da)	2013-01-07	Vaccineadjuvans
WO2003041735A3 (en)	2003-09-25	Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
WO2003066094A3 (en)	2003-12-24	Hepatitis b vaccines
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
ATE458496T1 (de)	2010-03-15	Hiv-vakzine und anwendungsverfahren
EP1395283A4 (en)	2005-06-08	HETEROLOGICAL PROTECTION, INDUCED BY IMMUNIZATION WITH THE INVAPLEX VACCINE
NO20024255D0 (no)	2002-09-06	HIV-immun adjuvansterapi
ATE431745T1 (de)	2009-06-15	Ltb4 als adjuvans für impfstoffe
SG147465A1 (en)	2008-11-28	Vaccine
GB2444676A (en)	2008-06-11	Adjuvanted vaccine
WO2000006198A3 (en)	2001-07-19	Adjuvant comprising pulmonary surfactant
WO2005123112A3 (en)	2006-04-27	Method of enhancing the immune response to a vaccine
AR026913A1 (es)	2003-03-05	Analogos de (1s-cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales